Due to the risk of CRS and neurologic toxicity, patients should be hospitalized for 48 hours after administration of all doses within the step-up dosing schedule
Disclosures: Emmanuel Dixon: Nothing to Disclose, thierry claudel: Nothing to Disclose, Jakob-Wendelin Genger: Nothing to Disclose, Ci Zhu: Nothing to Disclose, Alexander Nardo: Nothing to Disclose, Veronika Mlitz: Nothing to Disclose, Claudia Fuchs: Nothing to Disclose, Andreas Bergthaler: Nothing to Disclose, Paola Dongiovanni: Nothing to Disclose, Wilfried Ellmeier: Nothing to Disclose, Michael Trauner: Albireo: Grant/Research Support, Alnylam: Grant/Research Support, Cymabay: Grant/Research Support, Falk: Grant/Research Support, Gilead: Grant/Research Support, Intercept: Grant/Research Support, MSD: Grant/Research Support, Takeda: Grant/Research Support, Ultragenyx: Grant/Research Support, Abbvie: Travel Grants, Falk: Travel Grants, Gilead: Travel Grants, Intercept: Travel Grants, Janssen: Travel Grants, Abbvie: Advisor, Albireo: Advisor, BiomX: Advisor, Boehringer Ingelheim: Advisor, Falk Pharma GmbH: Advisor, Genfit: Advisor, Gilead: Advisor, Hightide: Advisor, Intercept: Advisor, Ipsen: Advisor, Janssen: Advisor, MSD: Advisor, Novartis: Advisor, Phenex: Advisor, Pliant: Advisor, Regulus: Advisor, Siemens: Advisor, Shire: Advisor, BMS: Speaking and Teaching, Falk: Speaking and Teaching, Gilead: Speaking and Teaching, Intercept: Speaking and Teaching, Ipsen: Speaking and Teaching, Madrigal: Speaking and Teaching, MSD: Speaking and Teaching, Medical Universities of Graz and Vienna: Co.Inventor of patents for medical use of norUDCA filed by 981 METABOLIC DYSFUNCTION DRIVES CD8 T CELL HYPERFUNCTION AND IMPAIRED TUMOR RESPONSES IN MOUSE MODELS OF ADVANCED LIVER DISEASE Jeff Li 1 Katrina Jorritsma 1 Natasha Campeau 1 Agatha Vranjkovic 2 Jood Madani 1 Torki Alothaimeen 2 Angela Cheung 3 Michele Ardolino 2 Angela Crawley 2 , 1 University of Ottawa, 2 Ottawa Hospital Research Institute, 3 The Ottawa Hospital Background: Prolonged liver insults in chronic HCV (cHCV) infection and metabolic dysfunction-associated liver disease (MASLD) lead to progressive liver damage and increased risk for hepatocellular carcinoma
When activated, NFkB regulates a variety of effector genes including antioxidants, ROS-producing proteins and pro-inflammatory genes (reviewed in 52 )
Lastly, a small sample size and unbalanced grouping can lead to errors in the analysis
73,74,75 While suppression of the immune response is necessary to limit tissue damage during inflammation, in certain diseases, such as sepsis and cancer, it can lead to a breakdown of the immune defense system
